These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 20172522)
21. Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids. Talaulikar VS; Manyonda I Eur J Obstet Gynecol Reprod Biol; 2012 Dec; 165(2):135-40. PubMed ID: 22901974 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment. Melis GB; Piras B; Marotto MF; Orru' MM; Maricosu G; Pilloni M; Guerriero S; Angiolucci M; Lello S; Paoletti AM Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):901-8. PubMed ID: 22681335 [TBL] [Abstract][Full Text] [Related]
23. Ulipristal acetate versus placebo for fibroid treatment before surgery. Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E; N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075 [TBL] [Abstract][Full Text] [Related]
24. [Ulipristal acetate (Esmya): a selective modulator of progesterone receptors, new treatment of uterine fibromatosis]. Nisolle M; Closon F; Firquet A; Top M; Pintiaux A Rev Med Liege; 2014 Apr; 69(4):220-5. PubMed ID: 24923103 [TBL] [Abstract][Full Text] [Related]
26. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues. Pérez-López FR Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187 [TBL] [Abstract][Full Text] [Related]
27. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Fiscella K; Eisinger S Obstet Gynecol; 2008 Sep; 112(3):707; author reply 707-8. PubMed ID: 18757682 [No Abstract] [Full Text] [Related]
28. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids. Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793 [TBL] [Abstract][Full Text] [Related]
29. Levonorgestrel inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Xu Q; Qiu L; Zhu L; Luo L; Xu C Contraception; 2010 Sep; 82(3):301-8. PubMed ID: 20705162 [TBL] [Abstract][Full Text] [Related]
30. Intrauterine progestins, progesterone antagonists, and receptor modulators: a review of gynecologic applications. Rodriguez MI; Warden M; Darney PD Am J Obstet Gynecol; 2010 May; 202(5):420-8. PubMed ID: 20031112 [TBL] [Abstract][Full Text] [Related]
32. An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review. Bartels CB; Cayton KC; Chuong FS; Holthouser K; Arian SE; Abraham T; Segars JH Clin Obstet Gynecol; 2016 Mar; 59(1):30-52. PubMed ID: 26756261 [TBL] [Abstract][Full Text] [Related]
33. Progesterone and progesterone receptor modulator in uterine leiomyoma growth. Maruo T Gynecol Endocrinol; 2007 Apr; 23(4):186-7. PubMed ID: 17505936 [No Abstract] [Full Text] [Related]
34. Levonorgestrel-releasing intrauterine system: uses and controversies. Bahamondes L; Bahamondes MV; Monteiro I Expert Rev Med Devices; 2008 Jul; 5(4):437-45. PubMed ID: 18573044 [TBL] [Abstract][Full Text] [Related]
35. Levonorgestrel releasing-intrauterine system for the treatment of menorrhagia and/or frequent irregular uterine bleeding associated with uterine leiomyoma. Socolov D; Blidaru I; Tamba B; Miron N; Boiculese L; Socolov R Eur J Contracept Reprod Health Care; 2011 Dec; 16(6):480-7. PubMed ID: 21942657 [TBL] [Abstract][Full Text] [Related]
36. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604 [TBL] [Abstract][Full Text] [Related]